Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02015169
Recruitment Status : Completed
First Posted : December 19, 2013
Last Update Posted : January 17, 2018
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center

Brief Summary:
We planned this study to investigate the efficacy and safety of XELOX (capecitabine and oxaliplatin) plus lapatinib treatment in HER2-positive gastric cancer patients with liver metastasis.

Condition or disease Intervention/treatment Phase
HER2-positive Gastric Cancer Patients With Liver Metastasis Drug: Lapatinib Phase 2

Detailed Description:

Gastric cancer is the leading cause of cancer death worldwide with the incidence of 18.9/100,000 per year and the mortality rate of 14.7/100,000 per year [1] and is the most common malignancy in Korea[2]. Metastatic gastric cancer remains a therapeutic challenge for medical oncologists due to poor prognosis. Several randomized phase III trials comparing combination chemotherapy such as 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM), or 5-FU, doxorubicin, and high-dose methotrexate (FAMTX) with best supportive care have demonstrated significantly prolonged overall survival (8 - 10 months) for chemotherapy group as compared to best supportive care alone (3 - 5 months)[3, 4].

In quest of a novel therapeutic target for gastric cancer, HER2 overexpression has been tested and was reported in 6-35% of stomach and gastroesophageal tumors [5]. Trastuzumab, a humanized monoclonal antibody which selectively targets HER2, has shown survival benefit in patients with HER2(+) metastatic breast cancer [6-8]. The ToGA trial is the first randomized, prospective, multicenter, phase III trial to study the efficacy and safety of trastuzumab in HER2(+) GC [9]. Of 3,807 tumor samples screened for Her2 status, 22.1% were Her2 positive and 594 patients were randomized to receive chemotherapy alone or chemotherapy + trastuzumab.

The ToGA trial demonstrated a significant survival benefit in the transtuzumab +chemotherapy when compared with chemotherapy alone arm: 13.5 vs. 11.1 months, respectively (p=0.0048; HR 0.74; 95% CI 0.60, 0.91). ORR was 47.3% in the trastuzumab + 5-FU/CDDP (or capecitabine/CDDP) arm and 34.5% in the chemotherapy alone arm (p=0.0017). The ToGA trial is the first phase III trial to demonstrate survival benefit from molecularly targeted agent in gastric cancer.

Of note, 70 - 80% of patients HER2 overexpressing breast cancer do not respond to trastuzumab due to either primary or acquired resistance. One of the important mechanisms for trastuzumab resistance is the accumulation of truncated forms of the HER2 receptor which lack the extracellular trastuzumab-binding domain (Figure 2). P95HER2, an amino terminally truncated carboxyl terminal fragments of HER2, is frequently found in HER2(+) breast cancer cell lines and tumor specimens (~20%)[11]. Intriguingly, recent study showed that p95HER2 (+) breast cancer cells were resistant to trastuzumab but remained sensitive to the antiproliferative effects of the tyrosine kinase inhibitor lapatinib, both in vitro and in vivo[11]. In addition, patients with p95HER2(+)breast cancer were resistant to trastuzumab with significantly lower response rate when compared with full-length HER2(+) breast cancer (11.1% vs 51.4%, respectively; P = 0.029).

We have surveyed the incidence of p95HER2 expression in fresh frozen tissues from gastric cancer and found that > 60% of HER2 (3+) GC demonstrated p95HER2. Hence, the role of lapatinib may be more promising than trastuzumab in GC HER2(+) patients with truncation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Actual Study Start Date : July 9, 2012
Actual Primary Completion Date : July 17, 2017
Actual Study Completion Date : November 17, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Experimental: XELOX+lapatinib

D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs

D1-D14 Capecitabine 850mg/m2 p.o bid

D1 ~ Lapatinib 1250 mg qd dailiy

Drug: Lapatinib
lapatinib 1250mg qd daily up to 8 cycles (3 weeks * 8 cycles = 24 weeks)
Other Name: Tykerb, GSK

Primary Outcome Measures :
  1. complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor). [ Time Frame: after surgery, up to 3weeks ]

Secondary Outcome Measures :
  1. response rate based on RECIST 1.1 [ Time Frame: every 3 cycles, up to 24weeks ]
  2. disease-free survival [ Time Frame: after surgery, every 3 months ]
  3. progression-free survival [ Time Frame: every 3 cycles for 6 months and ten every 3 months up to 3 years ]
    from date of study enrollment until the date of first documented progression or date of death from any cause, whichever came first

  4. safety and toxicity based on NCI CTCAE ver. 4.0 [ Time Frame: every cycles, up to 24 weeks ]
    Number of participants with adverse events

  5. Exploratory biomarker analysis [ Time Frame: every 3 cycles, up to 24weeks ]
    change in circulating tumor cells, HER2 positivity in primary and metastatic tumors, Receptor tyrosine kinase activation profiling including total HER1, HER2, HER3, phosphorylated HER1, HER2, HER3 - Prometheus, USA, Correlation between response rate and p95HER2 (truncated HER2)) Correlation between RR and RNA sequencing (all available tissue specimens)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically proven gastric cancer with metastatic lesion(s) that is (are) unresectable

    • locally advanced gastric cancer that are NOT resectable
    • distant metastases limited to abdominal lymph node, liver only :Patients with liver metastasis : Number of liver metastasis between 2 and 5 or maximal diameter should be under 5 cm (2 = liver mets = 5 or maximal diameter = 5cm) No LN metastasis within group 3 and no bulky N2 metastasis Clinically no distant metastasis (lung metastasis, mediastinal LN metastasis, neck LN metastasis, bone metastasis, brain metastasis, and peritoneal seeding in abdominal and pelvis CT; in cases of suspicious peritoneal seeding in imaging without any evidence of ascites and/or peritoneal enhancement will be allowed to enter the study based on investigators' decision)
    • chemo-naïve (adjuvant treatment will be allowed if the last date of treatment is ≥ 6 months from the study entry date
  2. Age ≥ 18
  3. ECOG performance 0 - 1
  4. Adequate organ function (AST and ALT ≤2x upper limit of normal, bilirubin ≤1.5 x upper limit of normal, and creatinine < 1.5x upper limit of normal, platelet > 100,000/ul, absolute neutrophil count ≥ 1,500/ul)
  5. At least one measurable lesion by RECIST 1.1 criteria
  6. HER 2 (+) by HercepTest(IHC 3+ alone, or IHC 2+ with FISH amplification)
  7. Written informed consent

Exclusion Criteria:

  1. Prior therapy for metastatic disease
  2. Pregnant or lactating women
  3. Uncontrolled medical illnesses including medically uncontrolled infection, uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months
  4. Any comorbidities which are not suitable for general anesthesia and surgical resection
  5. Distant metastases other than liver or abdominal lymph nodes (As outlined in inclusion criteria, and peritoneal seeding in abdominal and pelvis CT; in cases of suspicious peritoneal seeding in imaging without any evidence of ascites and/or peritoneal enhancement will be allowed to enter the study based on investigators' decision)
  6. Known immediate or delayed hypersensitivity reaction to lapatinib ,capecitabine, oxaliplatin or any other platinum compounds, any recipients.

8) Subjects with DPD deficiency 9) Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment) 10) Pre-existing hand and foot syndrome and peripheral neuropathy of grade 2 or greater 11) Subjects unsuitable to resection or general anesthesia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02015169

Layout table for location information
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Korea, Republic of, 135-720
Sponsors and Collaborators
Samsung Medical Center
Layout table for investigator information
Principal Investigator: Jeeyun Lee, MD, PhD Division of Oncology, Department of Medicine, Samsung Medical Center

Layout table for additonal information
Responsible Party: Jeeyun Lee, Professor, Samsung Medical Center Identifier: NCT02015169    
Other Study ID Numbers: 2012-05-078
First Posted: December 19, 2013    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018
Keywords provided by Jeeyun Lee, Samsung Medical Center:
gastric cancer
neoadjuvant chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Stomach Neoplasms
Liver Neoplasms
Neoplastic Processes
Pathologic Processes
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Liver Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors